M | O | C Cancer Care & Research Centre has achieved a significant milestone by successfully discharging its first patient treated with CAR-T cell therapy for Relapsed Refractory Diffuse Large B-cell lymphoma (DLBCL). This marks M | O | C as one of the pioneering community cancer care institutions in India to offer this cutting-edge and life-saving treatment.
The patient, a 60-year-old resident of Thane, had battled relapsed and refractory lymphoma for over three years, having undergone three unsuccessful treatment regimens, including immunotherapy. After receiving CAR-T therapy, the patient experienced no complications and was discharged in stable condition.
CAR-T (Chimeric Antigen Receptor T-cell) therapy represents a breakthrough in cancer treatment. The process involves genetically modifying the patient’s own T-cells to specifically target and eliminate cancer cells. By utilising the immune system’s potential, this therapy offers a new lifeline for patients with aggressive and otherwise untreatable blood cancers.
The therapy at M | O | C was facilitated in partnership with ImmunoACT, whose expertise in CAR-T cell manufacturing made this transformative treatment possible.
Dr. Suraj Chiraniya, Hemato-Oncologist and BMT Specialist at M | O | C, emphasised the significance of the achievement: “CAR-T therapy is particularly vital for patients with relapsed and refractory lymphomas who have limited options after conventional treatments fail. This milestone marks a new era in oncology care.”
His colleague, Dr. Ashray Kole, added, “This successful treatment demonstrates the potential of CAR-T therapy to revolutionise cancer care in India, offering renewed hope to patients and their families.”
Key Highlights of the Case
Patient Details: 60-year-old male from Thane, Mumbai
Condition: Relapsed Refractory Diffuse Large B-cell lymphoma (DLBCL)
Treatment Timeline: Admitted on November 5, 2024; discharged on November 24, 2024
Background: Failed three prior treatments, including immunotherapy
Outcome: Achieved successful remission post-CAR-T therapy
_20241226144814_original_image_13.webp)
